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UTILITY OF PLASMA BIOMARKERS IN THE VALIDATION OF REPORTED LOC &
PTA FOR GCS 13-15 PATIENTS: A TRACK-TBI PILOT STUDY

Jeffrey Brennan BS, MS
The University of Texas
School of Public Health, 2020

Thesis Chair: Marcia C de Oliveira Otto, PhD
Depending on a brain injury patient to accurately report their duration of
unconsciousness and amnesia is clearly flawed. We constructed biomarker-based
models to validate these self-reported measurements using a GCS 13-15 subset of
participants from TRACK-TBI, a multi-institutional study on traumatic brain injury.
Potential covariates were assessed for significant interactions with biomarker level.
We report that the predictions of LOC and PTA failed. GFAP exhibited the most
consistent serum level increase between categories of both LOC and PTA. Given a
number of issues with the study sample, we recommend continued investigation on
the prediction of LOC and PTA using a larger database.
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BACKGROUND
Epidemiology of TBI
Traumatic brain injury (TBI), a condition commonly associated with contact
sports and military combat, disproportionately affects the elderly. Patients older than
74 have the highest rate of TBI related hospital visits out of any age group with an
incidence of 2.2 per 100 people.1 This doubles the next highest adult rate of 1.1 per
100 people between the ages of 15 and 24.1 Every year, 69 million people suffer
TBI, with mild TBI (mTBI) – a classification characterized by shorter durations of
unconsciousness and reduced impairment of cognitive function – comprising 81% of
those cases.2 Falls are the leading cause of injury among all age groups, with an
incidence of 0.4 per 100 people.1 Moreover, the risk of adverse outcomes like
dementia from a single mTBI event increases with age. Compared to trauma
patients without TBI, hazard ratios of dementia increase from 1.08 (95% Confidence
Interval: 0.77 – 1.49) among mTBI patients aged 55-64 to 1.25 (95% Confidence
Interval: 1.09 – 1.44) for mTBI patients older than 85.3
The elderly simultaneously face the highest incidence of TBI visits, the most
common cause of injury, and the most severe consequences from a single mTBI
event. Despite this overwhelming burden, diagnostic guidelines remain inconsistent
and depend on self-reported measures. These measures are subject to recall bias,
especially for injuries where no witness was present. This is particularly problematic
in elderly populations, since approximately one in four people older than 65 live
1

alone.4 To address this limitation, it is crucial to improve current diagnostic methods
and explore objective measures that minimize reporting bias.

Clinical Approach to TBI
When a patient seeks care for their head injury, the receiving physician’s
diagnosis is critical. Current guidelines suggest a diagnosis of mTBI when one of the
following conditions are present: 1) a loss of consciousness (LOC) period – where
the patient was unaware of themselves and their surroundings – lasting less than 30
minutes; 2) post-traumatic amnesia (PTA) – where the patient is unable to
remember events after the injury – lasting less than 24 hours; 3) a Glasgow Coma
Scale (GCS) score – a brief battery to assess verbal, motor, and visual function –
between 13 and 15; 4) presence of physiological symptoms such as vomiting,
headaches, and disorientation.5,6
If the physician diagnoses a patient with TBI when they don’t have it, their
patient may have to pay for an unneeded treatment. For example, the physician may
request a computed tomography (CT) scan to check for skull damage,7 a magnetic
resonance image (MRI) to check for brain bleeds,8 and may even suggest that the
patient goes to regular physical therapy to regain motor function.9
On the other hand, if the physician fails to diagnose TBI when it is present,
the opportunity for time-sensitive intervention may be missed. In the short term, the
patient’s balance will be impaired,9 which could lead to another fall if they are sent
2

home too early. mTBI is associated with increased risk for subsequent neurological
disease, including Parkinson’s Disease, Alzheimer’s Disease, and cognitive
impairment.10 In the long term, the patient may miss the opportunity for preventative
intervention. For example, anti-inflammatory drugs like ibuprofen can protect against
the onset of Parkinson’s10 and Alzheimer’s Disease.11 A misdiagnosis means that
the patient will be unprepared for their increased risk.
GCS scores primarily drive TBI diagnosis, however there is criticism
regarding the limitations of this method.12–15 TBI defined by GCS score includes only
three classifications – mild (GCS 13-15), moderate (GCS 9-12), and severe (GCS 38).17 GCS 13-15 patients are at increased risk of depression, post-concussion
symptoms, and attention deficits even a year after their injury.17 Yet, these patients
are classified as having “mild” TBI, which is confusing to both the patient and their
loved ones. Moreover, GCS results are impacted by patient intoxication, which often
presents together with head trauma.18,19 Diagnostic limitations stemming from the
simplicity of the GCS have prompted the call for a nuanced classification scheme.
Brain trauma is complex, and classification should consider multiple clinical features
of brain injury20 including demographic factors,21 radiologic findings,22 and the
durations of LOC and PTA.20
To inform a refined classification of TBI and ensure that care is appropriately
directed, reported durations of LOC and PTA must be accurate. Recall bias plagues
the clinical utility of self-reported LOC and PTA, especially when the head injury was
3

not observed by a witness. Objective biomarkers that are associated with brain
trauma can be expected to validate these subjective estimates, and improve the
resulting patient plan for care.

Plasma Biomarkers
In response to the inherent limitations of subjective measures, neurotrauma
researchers have investigated biomarkers associated with TBI. Currently identified
blood-based biomarkers include Glial Fibrillary Acidic Protein (GFAP), Ubiquitin CTerminal Hydrolase L1 (UCH-L1), phosphorylated tau (P-Tau), and total tau. After a
brain injury, proteins associated with neural function are released into the
bloodstream.23 GFAP is a protein that regulates the repair of astrocytes, which
transmit electrical signals in the brain. Elevated plasma levels of GFAP have been
observed to correlate with brain injuries where astrocyte cells are damaged.23 UCHL1 is an enzyme found in neuron cells. After a TBI, UCH-L1 is cleaved from
damaged neurons and can be found elevated in blood.23 Tau serves as a binding
protein that absorbs the shock from a rapid head movement, such as the whiplash
from a car accident.23 Under stress, tau proteins are excessively phosphorylated.
Total tau count alone is not informative for TBI. However, phosphorylated tau (PTau) (AUC = 0.711; p<0.001) and the ratio of P-Tau to total tau (AUC = 0.748;
p<0.001) are able to differentiate TBI severity.24 These four biomarkers are well-
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studied in their relation to TBI and represent different characteristics of brain
damage.

Gap in Knowledge
Although LOC and PTA are key factors informing TBI diagnosis, literature
regarding biomarker methods to improve their reliability are lacking. Studies in this
field typically consider the prognostic value of biomarkers, such as correlations with
functional outcome and recovery at 3 and 6 months.26,27,29–32 Recent studies have
extended these findings by predicting outcomes with multivariate biomarker
panels.32–34
In order to develop an accurate TBI classification scheme, biomarkers need
to validate subjective indicators of brain damage. Several studies have identified
significant associations between LOC/PTA and radiologic findings (CT7,33,34,
MRI35,36). However, these imaging tests are expensive and MRI testing is
uncommon for GCS 13-15 patients.37 Plasma biomarkers offer a cheaper alternative
to quickly validate these self-reported measures at the time of injury.

Research Question
To determine if a panel of plasma biomarkers (GFAP, UCH-L1, P-Tau, total
tau), adjusted for potential covariates (age, sex, time between injury and blood
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draw), can predict the presence of LOC, and separately, the presence of PTA, in a
population of GCS 13-15 hospital patients with potential brain injuries.

Study Aims
1. To determine the efficacy of a four-item plasma biomarker panel (GFAP,
UCH-L1, P-Tau, total tau) adjusted for potential confounders (i.e. age, sex,
time between injury and blood draw) in correctly classifying the presence of
LOC in a population of 136 hospital patients from three sites (San Francisco,
Pittsburgh, Austin) with diagnosed potential mild TBI and a recorded duration
of LOC. The efficacy of plasma biomarkers were quantified using the area
under the curve (AUC) from a receiver operating characteristic (ROC) curve.

2. To determine the efficacy of a four-item plasma biomarker panel (GFAP,
UCH-L1, P-Tau, total tau) adjusted for potential confounders (i.e. age, sex,
time between injury and blood draw) in correctly classifying the presence of
PTA in a population of 114 hospital patients from three sites (San Francisco,
Pittsburgh, Austin) with diagnosed potential mild TBI and a recorded duration
of PTA. The efficacy of plasma biomarkers were quantified using AUC.
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Hypotheses
1. We expect that the LOC biomarker panel will be able to predict the presence
of LOC in a test subset of TRACK-TBI Pilot patients with a higher AUC than
the PTA panel for predicting the PTA model.

Public Health Significance
The expected outcomes from the proposed project are a validated prediction
of LOC and PTA using plasma biomarkers. We expect that findings from this study
will promote additional research on validating the clinical indicators of TBI. Currently,
discrepancies in TBI diagnosis between medical professionals are unfortunately
common.38,39 These insufficient classifications result in missed cases and limit
opportunities for early intervention. With a revised classification scheme, at-risk
patients will have a better chance of receiving the care they need, and the severity of
long-term neurological impacts can be limited with preventative measures.

METHODS
Parent Study Design & Population
TRACK-TBI is currently the largest study of American TBI patients.40 A pilot
study was conducted to assess the feasibility of the ongoing U01 and LONG studies.
Members of the pilot study were patients ascertained from one of three level one
trauma centers (University of California – San Francisco; University of Pittsburgh
7

Medical Center; University Medical Center Brackenridge). between April 1st, 2010
and September 30th, 2010. This population includes 300 suspected TBI patients.40
Study participants were approached by study personnel during peak hospital
hours, contingent on their medical records matching the eligibility criteria for TRACKTBI. Ability to consent was determined using the Galveston Orientation and Amnesia
Test or the presence of a legally authorized representative.40 Participants were
compensated for their time.
Patients were provided consent forms and self-selected into different subsets
of the study. All patients who consented provided their medical history and CT scan
results as part of standard emergency department care. A subset of these patients
additionally consented to a standard blood draw for proteomic markers, including
GFAP, UCH-L1, P-Tau, and total tau. Inclusion and exclusion criteria varied by the
study subset (Appendices A & B). Since all data was collected within 24 hours of
injury, TRACK-TBI provides a unique opportunity to assess the relationship of
biomarkers and TBI diagnostic criteria.

Study Population
In this analysis, we will include participants with suspected TBI. Participants
must have recorded levels for at least 3 of 4 biomarkers (GFAP, UCH-L1, P-Tau,
total tau) collected within 24 hours of their injury. Suspected TBI patients must have
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a recorded duration of either LOC or PTA (including missing and unknown
durations), and a GCS score between 13 and 15.

Study Design
The proposed study is a cross-sectional study on the diagnostic utility of
plasma biomarker levels for identifying the presence of LOC and PTA using a subset
of TRACK-TBI Pilot participants.

Exposures
The main exposures are biomarker levels of GFAP, UCH-L1, P-Tau, and total
tau. Biomarker levels were obtained within 24 hours of patient injury. 8 ml of blood
was drawn from the patient’s vein, unless an arterial line was already installed as
part of standard care. Blood samples were centrifuged for 7 minutes at 4000 RPM,
separated into plasma and serum, then frozen at ‐80°C.40 Samples were sent to a
biorepository at the UCSF DNA Bank at Mission Bay for storage and analysis.40

Outcomes
The outcomes for this study are presence of LOC and PTA. Both measures
were obtained by an interview of either the participant or a witness. To assess LOC,
participants were asked “Did you have a period of time after the event when you
were completely unconscious. That means you had no ability to think, speak or
9

move and were completely unaware of the world around you.”40 Witness reports
were utilized to determine LOC when available. To assess PTA, participants were
asked “Was there a period of time after the injury for which you have no memory? If
so, how long did it take for your memory to return to normal or become consistent.”
40

Covariate Assessment
Following head trauma, the levels of particular biomarkers are expressed
depending on the age of the patient, as well as the time between trauma and when
their blood was drawn. These factors, along with other potential covariates
(Appendix C) were assessed for their association with biomarkers in the prediction of
LOC & PTA. The values for all covariates were obtained from patient medical
records and interviews at the study sites. If these covariates are not considered,
then the biomarker-based logistic regression model will have a higher chance of
incorrectly classifying the LOC and PTA of patients who are outliers for these
factors.

Data Analysis
Demographics and Outcome Relationships
All biomarker levels were assessed for normality using Shapiro-Wilk tests,
boxplots, and normal probability plots. If a biomarker exhibits normality as indicated
10

by the normal probability plot and a Shapiro-Wilk p-value > 0.05, then parametric
statistical tests of association were used to analyze their relationship with LOC and
PTA. Otherwise, we will use nonparametric tests to obtain these associations.
Wilcoxon Rank Sum non-parametric tests were ultimately chosen to analyze the
relationship between biomarkers and the presence of LOC and PTA.

Covariates & LASSO
A least absolute shrinkage and selection operator (LASSO)42 identified
covariates (Appendix C) in the data. LASSO is a shrinkage method that aids in
model selection by identifying predictors which are most likely to be important in the
prediction of LOC/PTA. While fitted values are typically computed using least
squares, LASSO uses an additional lambda parameter to minimize the potential
variance of model predictions. Predictors that exhibit a large degree of variation (and
therefore not predictive of the outcome), have their beta coefficients shrunk to 0,
excluding them from the model.43
LASSO was implemented using the cv.glmnet() function from the glmnet
package in r. A matrix of all predictors was cross-validated using the default
parameters of 10 folds and no variable weighting. The resulting lambda values were
used to compute beta coefficients of the model. If the coefficient was shrunk to 0,
then the predictor was not included in the model.
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Model Fitting
Biomarker models were fit using logistic regression based on potential
covariates (Appendix C) for dichotomized groups of LOC and PTA. LOC and PTA
models was trained using two-thirds of the GCS 13-15 sample. The remaining onethird of the sample was used to report the findings to account for potential overfitting
of the training data.44 The training process is described as follows: a) LASSO
identifies predictors for the LOC and PTA models. b) Model diagnostics (linearity,
multicollinearity, outliers) are reviewed (detailed below). If model assumptions are
violated, remedial measures (transformations, investigation of outliers and
extraneous variables) were taken (detailed below).

Diagnostics
Linearity
For a logistic regression models, linearity was assessed between continuous
predictors and the log odds of LOC/PTA.45 A scatter plot matrix of all continuous
predictors was constructed with the log odds of LOC/PTA, and a restricted cubic
splines curve was applied to each continuous variable and visualized in the scatter
plot with the geom_smooth() r function to identify deviations from normality. For
predictors which visually appear to be nonlinear, this relationship was quantified by
conducting a likelihood ratio test that compares a model with the linear term with a
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restricted cubic spline transformed predictor. If the resulting p-value was > 0.05, then
the predictor was transformed with the spline terms.

Multicollinearity
Multicollinearity occurs when two predictors are strongly correlated with each
other. Since the interpretation of coefficients from a multivariable model assumes
that all other predictors are held constant, multicollinearity will inhibit model
interpretation.44 A variance inflation factor (VIF) was used to identify multicollinearity
using the vif() function from the car package in r. If the VIF value between two
predictors was greater than 10, multicollinearity was addresed.44

Outliers
Outliers are defined as extreme observations that strongly influence either the
fitted values or other regression coefficients in a statistical model.44 Outliers were
assessed visually by comparing the fitted model’s estimated probability against the
leverage, change in Pearson chi-square, and Cook’s distance.46 Leverage is
computed as the diagonal elements of the model’s hat matrix, which equals xj(X’VX)1x

j and

serves as an indicator of distance from the computed mean value of the full

model data.46 The change in Pearson chi-square is computed as the model’s
squared residuals divided by 1 – the diagonal elements from the model’s hat
matrix.46 Cook’s distance is calculated as the squared model residuals multiplied by
13

the diagonal elements of the hat matrix divided by 1 – the diagonal elements of the
hat matrix.46 Observations exhibiting large values (leverage values > 0.2, change in
Pearson chi-squared values > 3, Cook’s Distance values greater than > 0.2 with >
0.8 estimated probability) were declared as potential outliers and investigated
further.

Remedial Measures
If linearity fails, then the predictor was transformed using restricted cubic
splines.44 If multicollinearity is present, then the violating predictors were
investigated.44 If an outlier exceeds one of the three cutpoints, then it was
investigated and removed from the model if determined to be an error in the data by
a subject matter expert.44 After these remedial measures were taken, model
selection and diagnostics were conducted again as described above.

Interaction
Interaction is defined as when one predictor alters the magnitude of the
relationship between a predictor and the outcome (LOC or PTA).44 To identify
interaction terms, pairwise interactions were computed on the main effects from the
LASSO selected model. Next, a series of likelihood ratio tests were used to compare
the model with one of the interaction terms to the LASSO selected model with the
main effects but no interaction term. If the test has a p-value < 0.05 / n, where n is
14

the number of computed pairwise interactions, then the interaction term was
included in the model.

Model Analysis
The sensitivity and specificity for all models were visualized using receiver
operating characteristic (ROC) curves. LOC and PTA were predicted using the fitted
models from the training set on the remaining third of the GCS 13-15 patients. Once
the LOC and PTA models met all regression assumptions, two finalized model were
reported with a log-odds cutpoint that favored higher sensitivity in the respective
ROC curve.

RESULTS
Demographics and Outcome Relationships
Table 1. Demographics of TRACK Pilot GCS 13-15 Patients (n=178)
Overall (N=178)
Age
Mean (SD)

42.6 (17.9)

Range

16.0 - 93.0

Sex
Male

124 (69.7%)

Female

54 (30.3%)

Race*
White

146 (82.0%)

Black

16 (9.0%)

15

Overall (N=178)
Asian

7 (3.9%)

Unknown

7 (3.9%)

American Indian

1 (0.6%)

Pacific Islander

1 (0.6%)

Study Site
San Francisco

70 (39.3%)

Pittsburgh

60 (33.7%)

Austin

48 (27.0%)

Glasgow Coma Scale Score
15

146 (82.0%)

14

29 (16.3%)

13

3 (1.7%)

Mechanism of Injury*
Fall

63 (35.4%)

Motor Vehicle

35 (19.7%)

Assault

24 (13.5%)

Striking

23 (12.9%)

Self-Inflicted

17 (9.6%)

Firearm

10 (5.6%)

Piercing

5 (2.8%)

Other

1 (0.6%)

Time Between Injury and Blood Draw (min)
Mean (SD)

648.9 (400.7)

Range

30.0 - 1433.0

*Race was not included as a variable in the LOC and PTA models. Mechanism of
injury was collapsed into “Fall” and “Other” to avoid overweighting injury
mechanisms with infrequent counts.
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Patients from the TRACK Pilot were 42.6 years old on average (±17.9 years),
with the youngest enrolled patient at 16 and the oldest at 93 in this sample. The
majority of patients were male (69.7%) and white (82.0%). Of the three study sites,
San Francisco enrolled the most patients (70 which constituted 39.3% of the GCS
13-15 sample). Most patients had a GCS score of 15 (82.0%), indicating that they
did not exhibit any noticeable signs of impaired consciousness at the time of
assessment. Most patients were admitted to the hospital after a fall (35.4%). Other
more severe injuries comprised a sizeable portion of the sample: motor vehicle
accidents (19.7%), assaults (13.5%), self-inflicted injuries (9.6%), and injuries from a
firearm (5.6%). Patients were seen enrolled and evaluated soon after their injury,
with a mean blood draw time of 10 hours, and a maximum delay of less than 24
hours.

Table 2. Comparison of LOC Model Predictors by LOC Status (n = 178)
LOC+ (N=101)

LOC- (N=35)

Unknown (N=42)

p value
0.1301

Age
Mean (SD)

39.9 (15.9)

47.1 (21.3)

45.2 (18.8)

Range

16.0 - 76.0

18.0 - 93.0

16.0 - 77.0
0.9772

Sex
Male

71 (70.3%)

24 (68.6%)

29 (69.0%)

Female

30 (29.7%)

11 (31.4%)

13 (31.0%)
0.0563

Study Site
San Francisco

40 (39.6%)

19 (54.3%)

11 (26.2%)

Pittsburgh

31 (30.7%)

12 (34.3%)

17 (40.5%)

17

Austin

LOC+ (N=101)

LOC- (N=35)

Unknown (N=42)

30 (29.7%)

4 (11.4%)

14 (33.3%)

p value

0.1503

Glasgow Coma Scale
Score
15

81 (80.2%)

33 (94.3%)

32 (76.2%)

14

17 (16.8%)

2 (5.7%)

10 (23.8%)

13

3 (3.0%)

0 (0.0%)

0 (0.0%)
0.9882

Mechanism of Injury
Fall

36 (35.6%)

12 (34.3%)

15 (35.7%)

Other

23 (65.7%)

65 (64.4%)

27 (64.3%)
0.3381

Time Between Injury
and Blood Draw (min)
Mean (SD)

609.1 (389.6)

706.46 (436.7)

696.62 (394.7)

Range

30.0 - 1410.0

50.0 - 1412.0

58.0 - 1433.0

LOC+ indicates a loss of consciousness duration greater than 0 minutes. LOCindicates a duration of 0 minutes. P-values < 0.05 declared significant.
1. Kruskal-Wallis Test
2. Chi-Square Test
3. Fisher Exact Test
After stratification of patient demographics by LOC, study site exhibited some
difference by LOC strata, but were not statistically significant at the selected alpha
value of 0.05. Those with a reported loss of consciousness were more likely to be
seen at the San Francisco location, while those with an unknown LOC status were
most likely to be seen at the Pittsburgh clinic. Patients with unknown LOC were
more likely to have been in a motor vehicle accident than those with reported LOC.
Moreover, patients with LOC were more likely to have suffered blunt force trauma
(striking) than either the LOC- or LOC unknown patients. Mechanism of injury, GCS,
18

and time between injury and blood draw were roughly homogenous across LOC
strata.

Table 3 - Comparison of PTA Model Predictors by PTA Status (n = 178)
PTA+ (N=72)

PTA- (N=60)

Unknown (N=46)

p value
0.1301

Age
Mean (SD)

39.6 (16.7)

43.3 (19.5)

46.4 (17.2)

Range

16.0 - 74.0

16.0 - 93.0

18.0 - 77.0
0.5382

Sex
Male

49 (68.1%)

40 (66.7%)

35 (76.1%)

Female

23 (31.9%)

20 (33.3%)

11 (23.9%)
< 0.0012

Study Site
San Francisco

24 (33.3%)

35 (58.3%)

11 (23.9%)

Pittsburgh

18 (25.0%)

14 (23.3%)

28 (60.9%)

Austin

30 (41.7%)

11 (18.3%)

7 (15.2%)
0.5183

Glasgow Coma Scale
Score
15

59 (81.9%)

51 (85.0%)

36 (78.3%)

14

12 (16.7%)

7 (11.7%)

10 (21.7%)

2 (3.3%)

0 (0.0%)

13

1 (1.4%)

0.7052

Mechanism of Injury
Fall

23 (31.9%)

22 (36.7%)

18 (39.1%)

Other

49 (68.1%)

38 (63.3%)

28 (60.9%)
0.0881

Time Between Injury
and Blood Draw (min)
Mean (SD)

587.9 (407.5)

650.9 (410.3)

741.6 (366.2)

Range

126.0 - 1433.0

50.0 - 1412.0

30.0 - 1380.0

PTA+ indicates a loss of consciousness duration greater than 0 minutes. PTAindicates a duration of 0 minutes. P-values <0.05 declared significant.
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1. Kruskal-Wallis
2. Chi-Square Test
3. Fisher Exact Test
Patients stratified by PTA exhibited a significant difference in study site that is
more pronounced than when stratified by LOC. Patients without PTA were primarily
seen in San Francisco, while patients without a reported PTA were primarily seen in
Pittsburgh. There were more unknown PTA durations (28) in the Pittsburgh clinic
than PTA+ (18) or PTA- (14). While the San Francisco site had primarily PTApatients, the Austin site had primarily PTA+ patients. Time between injury and blood
draw was, on average higher among the unknown group. Other demographics did
not exhibit considerable differences when stratified by PTA. Sex, GCS, and
mechanism of injury did not differ between PTA strata.

20

Fig 1a: Outcomes and Numeric Predictors
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Fig 1b: Outcomes and Categorical Predictors

22

The univariate relationships of all biomarkers, covariates, and outcomes that
comprise the LOC and PTA logistic regression models were visualized for a
preliminary understanding of their potential association. Moderately strong
correlations are observed for log(GFAP) and P-Tau (0.622), age and log(UCH-L1)
(0.473), log(GFAP) and T-Tau (0.419), P-Tau and draw duration (0.494). Numeric
predictors appear to vary by study site, with patients treated in Pittsburgh
contributing to higher values of log(GFAP), P-Tau, and time between injury and
blood draw than either San Francisco or Austin. Biomarker levels do not appear to
strongly differ by presence of LOC or PTA. There is a notable repetition of log
transformed GFAP levels at the lower end of the distribution, which represent the
lower limit of detection for the GFAP blood test. Although these measurements are
valid, the repeated values may have exerted influence over the final model
prediction.
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Fig 2: LOC & Biomarker Univariate Significance

Biomarker values are the key predictor of interest for this analysis. We
conducted Wilcoxon Rank Sum tests for each biomarker with LOC. Log(GFAP) and
log(GFAP/UCH-L1) exhibited statistically significant associations (0.0064 and
0.0099), respectively. For both biomarkers, the median level was elevated in LOC+
patients as compared to LOC- patients. However, the variance for both of these
biomarkers is large across LOC categories. There is not a consistent or distinct
increase in levels of log(GFAP) or log(GFAP / UCH-L1) between LOC- to LOC+.

24

Fig 3: PTA & Biomarker Univariate Significance

There were no statistically significant associations observed for biomarker
levels and the presence of PTA. Similar to the LOC findings. Again, these
relationships are not consistent and do not provide a clear distinction between PTA
status. From these findings, biomarker levels alone do not appear to differentiate
between LOC or PTA.
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LOC Model Fitting
Table 4: LOC Initial Main Effects Model
LOC
Predictors

Odds Ratios

Confidence Interval

p

(Intercept)

5248.325

1.873 – 35700834.619 0.042

GFAP_log

1.477

0.888 – 2.620

0.149

UCHL1_log

1.276

0.375 – 4.406

0.694

P_TAU

1.462

0.380 – 6.014

0.583

T_TAU

0.921

0.835 – 1.008

0.080

Age

0.961

0.909 – 1.008

0.130

Draw_min

1.001

0.999 – 1.003

0.467

Sex [Female]

1.297

0.308 – 5.970

0.728

Site [Pittsburgh]

1.151

0.125 – 9.182

0.896

Site [Austin]

9.221

1.661 – 79.323

0.020

MechInjury [Other]

1.657

0.430 – 6.477

0.458

Observations
76
LOC: Loss of Consciousness
Draw_min: Time between injury and blood draw
Site: Study Site (“San Francisco” as the reference category)
Sex: Male used as reference category
MechInjury: Mechanism of Injury (“Fall” used as reference category)

A preliminary LOC model containing all potential main effects was fit for the
LASSO variable selection. The confidence interval for the intercept of 1.87 –
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35700834.62 indicates that this model is unstable and affected by the large
parameter odds ratios. The Austin study site was the only statistically significant
predictor (p = 0.020), with patients treated there having 9.22 the odds of being LOC+
as compared to San Francisco patients, holding all other predictors constant. The
primary biomarkers of interest do not exhibit statistically significant coefficients.
Given the extreme values present in the confidence intervals for this model,
additional remediation was required

Table 5: LOC Model with LASSO Selected Predictors
LOC
Predictors
(Intercept)

Odds Ratio Confidence Interval

p

1793.580 1.734 – 3411754.818 0.039

GFAP_log

1.575

0.995 – 2.675

0.067

T_TAU

0.934

0.856 – 1.012

0.101

Age

0.970

0.931 – 1.007

0.131

Draw_min

1.001

0.999 – 1.003

0.449

Site [Pittsburgh]

1.343

0.178 – 9.559

0.767

Site [Austin]

8.670

1.711 – 69.467

0.018

MechInjury [Other]

1.583

0.426 – 5.884

0.486

Observations
76
LOC – Loss of Consciousness
Draw_min – Time between injury and blood draw
T_TAU – Total-Tau
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After LASSO variable selection, several predictors were removed from the
preliminary model. The coefficients of log(UCH-L1), P-Tau, Sex, and Injury were
shrunk to 0, suggesting that these predictors were not predictive of LOC status.
Similar to the main effects model, the Austin site remains the only statistically
significant coefficient in this model, with patients treated in Austin having 8.67 times
the odds of being LOC+ as compared to patients from San Francisco, holding all
other predictors constant.
Pairwise interactions were fit on the LASSO selected main effects. When
compared to the full LASSO-selected model, no combination produced a likelihood
ratio test p-value less than 0.05 / n, where n was the number of pairwise
comparisons. Since the inclusion of an interaction term did not produce a
significantly different model, the simpler main effects model was chosen for
diagnostics and ROC analysis.
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Diagnostics
Linearity
Fig 4: LOC LASSO Model: Numeric Predictor Linearity Investigation

Numeric predictors from the LASSO model were visualized to assess the
underlying linearity assumption of the LOC model. There were four numeric
predictors in the LASSO selected LOC model: log(GFAP), T-Tau, Age, and time
between injury and blood draw. The values for each predictor was visualized against
the log-odds produced from the LOC model using a scatter plot and restricted cubic
splines. Age and time between injury and blood draw exhibited potentially non-linear
relationships to the log-odds of the model. Likelihood ratio tests comparing the LOC
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model to a model with a restricted cubic spline term replacing the predictor were
used to determine non-linearity.
Table 6: LOC LASSO Model: Time Between Injury and Blood Draw Non-Linearity
Investigation
Model 1: LOC ~ GFAP_log + T_TAU + Age + Draw_min + Site + MechInjury
Model 2: LOC ~ GFAP_log + T_TAU + Age + splines::bs(Draw_min) + Site +
MechInjury
Model
Resid. Df
Resid.
Dev Df
Deviance
Pr(>Chi)
1

68

67.813

2

66

65.883

2

1.9302

0.3809

Resid. Df – Residuals degree of freedom
Dev Df – Deviance degrees of freedom
Pr(>Chi): Chi-Squared p-value

With a p-value of 0.3809, there is not enough evidence to suggest that the
model containing a restricted cubic spline transformed time between injury and blood
draw significantly differs from the initial LASSO selected model. Time between injury
and blood draw was retained as a linear predictor for the remainder of the LOC
analysis.

Table 7: LOC LASSO Model: Age Non-linearity Investigation
Model 1: LOC ~ GFAP_log + T_TAU + Age + Draw_min + Site + MechInjury
Model 2: LOC ~ GFAP_log + T_TAU + Age + splines::bs(Draw_min) + Site + MechInjury

Model
1

Resid. Df
68

Resid.

Dev Df

67.813
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Deviance

Pr(>Chi)

2

66

62.614

2

5.1989

0.07431

Resid. Df – Residuals degree of freedom
Dev Df – Deviance degrees of freedom
Pr(>Chi): Chi-Squared p-value

With a p-value of 0.0743, there is not enough evidence to suggest that the
model containing a restricted cubic spline transformed age significantly differs from
the initial LASSO selected model at an alpha level of 0.05. Age was retained as a
linear predictor for the remainder of the LOC analysis in an effort to produce an
interpretable and stable final model.

Multicollinearity
Table 8 – Variance Inflation Factors of LASSO Selected Predictors – LOC Model
VIF
Df
GFAP_log 1.897653
1
T_TAU
1.438008
1
Age
1.213917
1
Draw_min 1.503269
1
Site
2.280941
2
MechInjury 1.131081
1
VIF – Variance Inflation Factor
Df – Degrees of Freedom
Since the coefficients of a logistic regression model are interpreted with the
other predictors held constant, the LASSO model was assessed for multicollinearity
to ensure that the selected predictors were not strongly related with each other. All
predictors exhibited a VIF value lower than the cutpoint of 10 for multicollinearity.
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The largest VIF observed was 2.28 for the study site predictor. These values are
within normal ranges and indicate that the model’s

Outliers
Fig 5: LOC LASSO Model: Leverage

Fig 6: LOC LASSO Model: Pearson’s Chi-Squared
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Fig 7: LOC LASSO Model: Cook’s Distance

Fig 8: LOC LASSO Model: Pearson’s Chi-Squared and Cook’s Distance
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There are five observations that exceed the leverage cutpoint of 0.2: 71, 51,
4, 17, and 5. (Figure 5). Observations 62, 61, and especially 72 exhibit a large
amount of influence on the probability from the model, and warrant further
investigation (Figure 6). The Cook’s distance plot indicates that observations 62 and
71 (Figure 7). When visualizing the change in Pearson chi-square using the
magnitude of leverage as the size of the points, the previously identified outliers all
exhibit relatively similar levels of leverage. Given this list of potential predictors,
observations 61, 62, and 72 were chosen for further investigation.

Table 9: Summary Statistics of Selected Outliers
LOC

GFAP_log

UCHL1_log

Min.

0

Min.

-2.0956

Min.

-2.071

1st

0

1st

-1.5199

1st

-1.858

Median

0

Median

-0.9442

Median

-1.645

Mean

0

Mean

-1.2985

Mean

-1.604

3rd

0

3rd

-0.8999

3rd

-1.371

Max.

0

Max.

-0.8557

Max.

-1.097

P_TAU

T_TAU

Age

Min.

1.45

Min.

79.22

Min.

1st

1.475

1st

80.19

1st

Median

81.17

Median

Median
Mean

1.5
1.883

Mean

82.8

Mean

Sex
23
25.5
28
38.33

3rd

2.1

3rd

84.59

3rd

46

Max.

2.7

Max.

88.02

Max.

64

Draw_min
Min.
1st
Median

Site
135
144.5
154

MechInjury

San Francisco

0

Fall

2

Pittsburgh

1

Other

1

Austin

2

34

Male

2

Female

1

Mean

406.3

3rd

542

Max.

930

These outliers all reported no duration of LOC despite having above average
levels of GFAP, and Total-Tau. The outliers were younger than the base population
(mean 38.33 compared to mean 42.59) and their blood was drawn earlier (mean
406.3 compared to mean 648.87). While these differences likely account for their
influence on the model predictions, the predictor values for these patients are not
extreme enough to justify removing them from the model. Moreover, their removal
did not produce notable improvements in model AUC. The suspected outliers were
retained in the final model.
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Model Performance
Fig 9: LOC LASSO Model: ROC Curve on Training Data

The LOC model achieved an area under the curve (AUC) of 0.773 on the
training set (n = 76). This model performance is acceptable, but unsurprising given
the lack of associations observed from the univariate analysis of model predictors.
The large values for decision cutpoints indicate that the model primarily predicted a
LOC+ outcome for patients in the training set.
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Fig 10: LOC LASSO Model: ROC Curve on Test Data

When the model fit on the training data was applied to the test data (n = 39),
the resulting ROC curve produced an AUC of 0.562 – which is marginally more
reliable than a random guess. The poor AUC indicates that the selected predictors
cannot reliably predict LOC in practice. The observed difference between the
training and test AUC suggests that the training model was based on unique
predictor-outcome relationships in the training set that were not generalizable to new
data.
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Table 10: LOC LASSO Model: Confusion Matrix
Reported (n=39)
Predicted
LOC+

LOC-

LOC+

2

8

LOC-

2

27

LOC: Loss of Consciousness
The following logistic regression model was fit on 76 patients from the training
set: LOC = 7.492 + 0.454GFAP - 0.069T-Tau – 0.069Age + 8e-4Draw_min + 0.295Site:Pittsburgh
+ 2.160Site:Austin + 0.459Injury:Other. Sensitivity was valued higher than specificity, and a
cutpoint of 0.47 was chosen to classify the fitted values from the model. With this
selection, the model produced a sensitivity of 0.5 and a specificity of 0.771 for an
overall accuracy of 0.7436 (Table 10).

PTA Model Fitting
Table 11: PTA Initial Main Effects Model
PTA
Predictors
(Intercept)

Odds Ratio

Confidence Interval

p

4247.471 2.897 – 16362410.646 0.033

GFAP_log

1.431

0.940 – 2.271

0.106

UCHL1_log

2.775

0.908 – 9.590

0.087

P_TAU

1.008

0.369 – 2.948

0.988

T_TAU

0.942

0.870 – 1.013

0.116
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Age

0.967

0.923 – 1.008

0.123

Draw_min

1.000

0.998 – 1.002

0.774

Sex [Female]

2.485

0.704 – 9.772

0.169

Site [Pittsburgh]

1.092

0.163 – 7.285

0.926

Site [Austin]

2.730

0.751 – 10.813

0.135

MechInjury [Other]

1.066

0.324 – 3.458

0.915

Observations
75
PTA: Post Traumatic Amnesia
Draw_min: Time between injury and blood draw
Site: Study Site (“San Francisco” as the reference category)
Sex: Male used as reference category
MechInjury: Mechanism of Injury (“Fall” used as reference category)
A preliminary PTA model containing all potential main effects was fit for the
LASSO variable selection. Similar to the first LOC model, the confidence interval for
the intercept of 3.77 – 14533149.24 indicates that this model is unstable and overfit
to the training data. There are no predictors that exhibit statistically significant
coefficients at an alpha value of 0.05.

Table 12: PTA Model with LASSO Selected Predictors
PTA
Predictors

Odds Ratio Confidence Interval

p

(Intercept)

3.905

0.455 – 40.073

0.227

GFAP_log

1.221

0.881 – 1.717

0.236

39

UCHL1_log

1.719

0.672 – 4.884

0.277

Site [Pittsburgh]

0.792

0.187 – 3.257

0.746

Site [Austin]

2.960

0.900 – 10.554

0.080

Observations
75
PTA – Post Traumatic Amnesia
Site: Study site (San Francisco as the reference category)
Many predictors were removed from the preliminary model after LASSO
variable selection. The coefficients of, P-Tau, Total tau, Sex, Injury, and time
between injury and blood draw were shrunk to 0, suggesting that these predictors
have no impact in the prediction of PTA. There are no statistically significant
coefficients in this restricted model. Pairwise interactions were fit on the LASSO
selected main effects. When compared to the full LASSO-selected model, no
combination produced a likelihood ratio test p-value less than 0.05 / n, where n was
the number of pairwise comparisons. Since the inclusion of an interaction term did
not produce a significantly different model, the simpler main effects model was
chosen for diagnostics and ROC analysis.
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Diagnostics
Linearity
Fig 11: PTA LASSO Model: Numeric Predictor Linearity Investigation

There were two numeric predictors in the LASSO selected PTA model:
log(GFAP) and log(UCH-L1). Both biomarkers appear to have approximately linear
relationships with the log-odds of the PTA model, and both likelihood ratio tests did
not produce a significant p-value. Both log(GFAP) and log(UCH-L1) were retained
as linear predictors in the PTA model for the remainder of the analysis.

Multicollinearity
Table 13: PTA LASSO Model: Variance Inflation Factors of Predictors
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VIF
Df
GFAP_log 1.203613
1
UCHL1_log 1.193526
1
Site
1.341334
2
VIF – Variance Inflation Factor
Df – Degrees of Freedom
All three exhibited a VIF value lower than the cutpoint of 10 for
multicollinearity. The largest VIF observed was 1.34 for the study site predictor.
These values are within normal ranges and do not indicate a violation of the no
multicollinearity assumption for logistic regression models.

Outliers
Fig 12: PTA LASSO Model: Leverage
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Fig 13: PTA LASSO Model: Pearson’s Chi-Squared

Fig 14: PTA LASSO Model: Cook’s Distance
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Fig 15: PTA LASSO Model: Pearson’s Chi-Squared and Cook’s Distance

There are no observations that exceed the leverage cutpoint of 0.2. (Figure
12). Observations 62, 71 exhibit a large amount of influence on the probability from
the model, with a change in Pearson’s chi-square larger than 3, and warrant further
investigation (Figure 13). The Cook’s distance plot indicates that observations 62
and 71 (Figure 14). When visualizing the change in Pearson chi-square using the
magnitude of leverage as the size of the points, the previously identified outliers all
exhibit relatively similar levels of leverage (Figure 15). Given this list of potential
predictors, observations 62 and 71 were chosen for further investigation.

Table 14: Summary Statistics of Selected Outliers
PTA
Min.

0

GFAP_log
Min.

-1.37833
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UCHL1_log
Min.

-1.0244

1st
Median
Mean
3rd
Max.

0
0
0
0
0

1st
Median
Mean
3rd
Max.

-0.91038
-0.44243
-0.44243
0.02553
0.49348

1st
Median
Mean
3rd
Max.

-0.9876
-0.9508
-0.9508
-0.9139
-0.8771

P_TAU
Min.
1st
Median
Mean
3rd
Max.

2.03
2.225
2.42
2.42
2.615
2.81

T_TAU
Min.
1st
Median
Mean
3rd
Max.

77.26
80.68
84.11
84.11
87.53
90.95

Age
Min.
1st
Median
Mean
3rd
Max.

43
45.75
48.5
48.5
51.25
54

Draw_min
Min.
1st
Median
Mean
3rd
Max.

225
232.5
240
240
247.5
255

Site
San Francisco
Pittsburgh
Austin

0
0
2

MechInjury
Fall
Other

Sex
Male
Female

2
0

0
2

Both outliers reported no duration of PTA despite having above average
levels of GFAP, UCH-L1. Both outliers were also enrolled at the Austin site. Their
blood was drawn earlier (mean 240 compared to mean 648.87), and neither suffered
a fall. While these differences likely account for their influence on the model
predictions, the predictor values for these patients are not extreme enough to justify
removing them from the model. Moreover, their removal did not produce notable
improvements in model AUC. The suspected outliers were retained in the final
model.
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Model Performance
Fig 16: PTA LASSO Model: ROC Curve on Training Data

The PTA model achieved an AUC of 0.711 on the training set, which is
acceptable but not excellent.47 Since no significant relationships were observed in
univariate analysis of PTA and the model predictors, this is expected. With a cutpoint
of 0.5 corresponding to a specificity of 0.5, the PTA produced fewer false positives
than the LOC model.
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Fig 17: PTA LASSO Model: ROC Curve on Testing Data

When the model fit on the training data was applied to the test data (n = 39),
the resulting ROC curve produced an area under the curve of 0.495 – which is
worse than a random guess. Similar to the LOC model, the low AUC observed for
the PTA model indicates that the selected predictors cannot reliably predict PTA
using the TRACK Pilot sample. The decrease in AUC between the training and test
ROC curves suggests that the training model performance was based on unique
predictor-outcome relationships in the training set that were not generalizable to new
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data. There were only three predictors selected for the model, including an indicator
of where the patient was treated. While there may have been a pattern of PTA status
by study site, this does not have biological relevance and would naturally make
incorrect predictions given a different set of data.

Table 15: Classification matrix – dichotomized PTA model
Reported
Predicted
PTA+

PTA-

PTA+

1

16

PTA-

2

20

PTA: Post Traumatic Amnesia
The following logistic regression model was fit: PTA = 1.3622 + 0.199log(GFAP)
+ 0.542log(UCHL1) – 0.234Site:Pittsburgh + 1.085Site:Austin. Sensitivity was valued higher than
specificity, and a cutpoint of 0.39 was chosen to classify the fitted values from the
model. With this selection, the model produced a sensitivity of 0.333 and a specificity
of 0.557 for an overall accuracy of 0.5385 (Table 15).
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DISCUSSION
In this cross-sectional study, we examined the utility of a plasma biomarker
panel adjusted for demographic covariates in the prediction of LOC and PTA. To our
knowledge, this is the first effort to do so. Our logistic regression models did not
reliably predict the presence of both LOC and PTA. Despite a modest classification
of each outcome in the training sets, these predictions were no better than random
guesses when applied to the test sets. log(GFAP) and log(GFAP / UCHL1) exhibited
univariate significance with LOC (Figure 2), however this association was weak and
disappeared when adjusted for other covariates in the LOC model. No significant
associations were identified in univariate comparisons of biomarker levels with PTA
(Figure 3).
Mechanism of injury was selected by LASSO as a predictor for the LOC
model. Falls were compared against “Other”, a collapsed category which included
more severe mechanisms of injury including gunshots, striking blunt force trauma,
and car accidents. There is evidence which suggests that both focal injuries (like
gunshots and piercing wounds) contribute to LOC as well as diffuse axonal injuries
(car accidents and blunt force trauma).48–51 However, our ability to utilize injury as an
outcome differentiator was limited by this grouping. Even with the initial injury
categories (Table 1), many key descriptors of the injury were absent. The severity of
injury from car accidents varies by collision type. Head-on collisions and high-speed
collisions with stationary objects typically produce the greatest alteration in
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consciousness.52 Lateral collisions also contribute to a disproportionate duration of
unconsciousness since seatbelts primarily limit forward movement.52 Further, focal
injury types did not describe which portion of the brain was affected, which strongly
contributes to the effects on consciousness and amnesia.51 Patients entering the ER
for a fall are typically older and exhibit more mild alterations in consciousness as
compared to car accidents, which makes age an important covariate for the LOC
model.53
GFAP and UCH-L1 were the two biomarkers selected in the LOC model.
GFAP was also selected in the PTA model. Additionally, GFAP exhibited a
significant univariate relationship with the presence of LOC. The GFAP finding is
consistent with other studies that have identified this biomarker as a key predictor of
TBI.54–59 Of note, elevated levels of GFAP are associated with focal injuries, while
elevated levels of UCH-L1 are associated with diffuse injuries on CT.60 This
relationship with injury type warrants further investigation. Although UCH-L1 is
associated with memory formation, LASSO did not select it as a predictor for PTA.61
For both outcomes, LASSO selected the study site as a key predictor. While
this improved the AUC for the training set, the relationship between LOC/PTA
outcome and where the patient was treated has no biological basis. All clinical sites
followed the same TRACK-TBI protocol, indicating that these differences were likely
due to random chance. The model was making outcome predictions based on where
the patient was treated, rather than more plausible associations like biomarker levels
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and mechanism of injury. The selection of this variable was expected after our
exploration in figure 1. Study site was a primary contributor to the variation in the
predictors of interest. More than sex or either outcome, study site was associated
with the largest difference in biomarker values, with higher levels consistently
observed for the Pittsburgh site. Study site also exhibited variation in the outcomes.
LOC+ and PTA+ cases were disproportionately treated in Austin.
Previous studies interested in prediction using TBI variables have focused on
CT findings, mortality, and neuropsychological test performance.20,62–65 The common
relationship with these studies is that they focused on concretely separate and easily
measurable outcomes. Since LOC and PTA are both self-reported and unreliable,
rigorous data collection and a large sample size are likely required to mitigate the
effects of misreported durations. In this analysis, we compared durations of 0
minutes for LOC and PTA against any duration greater than 0 minutes. The lack of
univariate biomarker associations observed for these collapsed levels may indicate
that the chosen split is not informative. A more discrete split in outcome duration (eg.
0 minutes compared to 30 minutes of LOC or PTA) may exhibit better prediction
performance. The 30-minute mark is classically used to differentiate mild from
moderate TBI5, and it would be useful to identify patients exhibiting alterations of
consciousness lasting this duration.
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CONCLUSION
Strengths
Previous efforts incorporating biomarker models in TBI studies have primarily
focused on 1) predictions of outcome32,66,67 (cognition, motor skills etc. as measured
by neuropsychological assessments) and 2) identification of TBI associated
biomarkers.68–71 Studies focused on the diagnostic criteria of TBI (LOC/PTA
duration) use costly approaches, such as handheld EEG devices.72 Our study
directly assesses the relationship of four distinct biomarkers with LOC and PTA
using a universal blood draw. Moreover, this blood draw was achieved with 24 hours
for all patients, which mitigates time-dependent level differences that occur in
biomarkers after injury.
TRACK-TBI is joined by other multi-institutional efforts to understand TBI.
CREACTIVE (n=7000)73 focuses on severe TBI, and CENTER-TBI (n=5400)74
focuses on TBI cases between ER, ICU, and hospital cohorts in Europe. TRACK
extends these efforts in America with a substantial collection of TBI-associated
genomic and proteomic markers. These markers, initially explored in the TRACK
Pilot, have been utilized in the larger TRACK U01 and LONG studies to identify
additional outcome associations. Since LOC and PTA are routinely collected as part
of standard TBI care, this study could be replicated in a larger patient cohort to
determine if the prediction inaccuracy stems from the small sample size or a true
lack of association between biomarkers and LOC/PTA. Through the stronger
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understanding of this relationship, we can improve the efficiency and targeting of
patient care.

Limitations
Study limitations originate from the small TRACK Pilot dataset and the
inherent limitations of self-reported measures. For binary logistic regression, 10
events per predictor (EPV) or more is recommended to produce a stable model.75
Others have argued that an EPV of 10 is too conservative and that an EPV of 5 - 9
observations is more realistic when considering many covariates.76 Our training
sample for LOC had 76 patients, and our training sample for PTA had 75 patients.
There were nine main effects (four biomarkers and five demographic covariates)
considered for each model. With only the main effects, there were 8.333
observations per predictor in the training models. This restricted our ability to include
pairwise interaction and polynomial terms. The test set for both models only had 35
observations and could ideally support 3 predictors, with a maximum of 7 using a
relaxed EPV of 5.
Together with a small sample size, predictors of the model were unbalanced.
There were very few female patients and patients with a GCS of 13 or 14. Most
importantly, the mechanism of injury – which is strongly linked with the pathology of
trauma – lacked sufficient observations for every category that was recorded. Levels
of the outcome were also unbalanced. There were 101 LOC+ patients, but only 35
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LOC- patients. We implemented a stratified train/test split to ensure that both sets
had an equal proportion of LOC+ and LOC- cases. However, the frequency of LOC+
cases meant that the model was assigning a log-odds of > 0.5 for the majority of
patients, resulting in many false positives when applied to the test set. This was also
observed for PTA model to a lesser degree. There were 72 PTA+ cases and 60
PTA- cases. In turn, a cutpoint of 0.5 corresponded to a sensitivity of 0.7 and a
specificity of 0.55, indicating that the distribution of PTA log-odds value was more
balanced.
Participants were incentivized to join the study and there was a lack of
patients older than 60. Male patients and injuries from car accidents were more
common than would be expected from the general population.77 Blood draws were
centrifuged and later analyzed at a separate facility. To validate LOC & PTA duration
in clinic, biomarker levels need to be measured much sooner. These limitations
could be improved in a larger study with LOC/PTA durations recorded in minutes
and biomarkers measured on-site with a rapid screening tool.

The selected biomarkers and covariates were not predictive of either LOC or
PTA, however an expanded study that utilizes a similar intake protocol with more
patients, study sites, and biomarkers (such as TRACK U01) may mitigate the
limitations identified in this pilot data.
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APPENDICES
A. TRACK-TBI Pilot Inclusion Criteria40
Component 1: Enrollment
1. Age 0-100
2. Documented/verified TBI (ACRM Criteria)
3. Injury occurred < 24 hours ago
4. Acute brain CT for clinical care
5. Ability to provide informed consent
Component 2: Blood Draw
1. Informed consent for the blood draw
2. Blood draw within 24 hours of presentation

B. TRACK-TBI Pilot Exclusion Criteria42
Component 1: Enrollment
1. Patients presenting later than 24 hours after their injury
2. Patients presenting who do not need a CT scan
3. Patients in custody or incarcerated
4. Patients who are a potential danger to themselves or others
Component 2: Blood Draw
1. Patients who do not consent to a blood draw
2. Two unsuccessful venipuncture attempts

C. TRACK-TBI Covariates of Interest40
Covariate

Values
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Age

Years

Time between
injury
and blood draw

Minutes

Sex
Study site
Mechanism of
Injury

•
•

Male
Female

1 – 3 (UCSF; UPMC; UMCB)
•
•
•
•
•
•
•

Assault
Direct impact: blow to head (striking)
Fall
Piercing fragment
Gunshot
Motor Vehicle
Self-inflicted
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